Amyloidosis, extramedullary plasmacytoma, and light chain deposition disease: impressive results of daratumumab therapy. - Suppr | 超能文献

Amyloidosis, extramedullary plasmacytoma, and light chain deposition disease: impressive results of daratumumab therapy.

作者信息

Wiklik-Dziadek Magdalena, Jaworek-Troć Joanna, Jurczyszyn Artur

机构信息

Department of Hematology, Jagiellonian University Medical College, Kraków, Poland

Department of Anatomy, Jagiellonian University Medical College, Kraków, Poland

出版信息

Pol Arch Intern Med. 2021 Mar 30;131(3):297-298. doi: 10.20452/pamw.15806. Epub 2021 Feb 11.

DOI:10.20452/pamw.15806

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Amyloidosis, extramedullary plasmacytoma, and light chain deposition disease: impressive results of daratumumab therapy.

Pol Arch Intern Med. 2021 Mar 30;131(3):297-298. doi: 10.20452/pamw.15806. Epub 2021 Feb 11.

2

Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.达雷妥尤单抗耐药在晚期多发性骨髓瘤患者中很常见，与 CD38 表达无关，与预后不良有关。

Eur J Haematol. 2018 May;100(5):494-501. doi: 10.1111/ejh.13046. Epub 2018 Mar 25.

3

Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.游离轻链分析在多发性骨髓瘤及相关病症诊断与管理中的应用

Scand J Clin Lab Invest Suppl. 2016;245:S113-8. doi: 10.1080/00365513.2016.1210337. Epub 2016 Jul 28.

4

Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis.对于接受皮下注射达雷妥尤单抗治疗的多发性骨髓瘤和轻链淀粉样变性患者，30分钟的标准监测时间和强度较低的预处理是安全的。

Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):566-568. doi: 10.1016/j.clml.2022.03.003. Epub 2022 Mar 9.

5

Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services.首个周期达雷妥尤单抗对多发性骨髓瘤和AL淀粉样变性治疗服务影响的真实世界数据。

Br J Haematol. 2018 Sep;182(6):936-939. doi: 10.1111/bjh.14897. Epub 2017 Aug 18.

6

Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?多药耐药性（P-糖蛋白）是意义未明的单克隆丙种球蛋白病、浆细胞瘤、多发性骨髓瘤和淀粉样变性患者浆细胞的固有特征吗？

Leuk Lymphoma. 1998 May;29(5-6):577-84. doi: 10.3109/10428199809050917.

7

Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience.达雷妥尤单抗治疗复发/难治性轻链型淀粉样变性患者的真实世界使用模式及疗效：单中心经验

Leuk Lymphoma. 2022 May;63(5):1246-1250. doi: 10.1080/10428194.2021.2018585. Epub 2022 Jan 2.

8

Daratumumab proves safe and highly effective in AL amyloidosis.达雷妥尤单抗在AL淀粉样变性中被证明是安全且高效的。

Br J Haematol. 2019 Apr;185(2):342-344. doi: 10.1111/bjh.15455. Epub 2018 Jun 25.

9

Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.达雷妥尤单抗、泊马度胺和地塞米松作为系统性轻链淀粉样变伴晚期心脏受累患者自体干细胞移植的桥接治疗。

J Oncol Pharm Pract. 2019 Jun;25(4):1021-1025. doi: 10.1177/1078155218815305. Epub 2018 Nov 26.

10

Daratumumab in multiple myeloma.达雷妥尤单抗在多发性骨髓瘤中的应用。

Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5.

引用本文的文献

1

A case of light chain deposition disease involving the kidney with a normal serum free kappa/lambda light chain ratio.一例累及肾脏的轻链沉积病，血清游离κ/λ轻链比值正常。

Ren Fail. 2022 Dec;44(1):103-105. doi: 10.1080/0886022X.2021.2021943.